Chapter 8. Natriuretic Peptides for Disease Monitoring in Patients with Chronic Heart Failure

  1. James A. de Lemos MD Associate Professor of Medicine Coronary Care Unit Director
  1. Richard W. Troughton MB, PhD and
  2. A. Mark Richards MD, PhD, DSc

Published Online: 13 JAN 2009

DOI: 10.1002/9781444300208.ch8

Biomarkers in Heart Disease

Biomarkers in Heart Disease

How to Cite

Troughton, R. W. and Richards, A. M. (2008) Natriuretic Peptides for Disease Monitoring in Patients with Chronic Heart Failure, in Biomarkers in Heart Disease (ed J. A. de Lemos), Blackwell Publishing Ltd., Oxford, UK. doi: 10.1002/9781444300208.ch8

Editor Information

  1. University of Texas Southwestern Medical Center Dallas, TX, USA

Author Information

  1. Christchurch Cardioendocrine Research Group, Department of Medicine, University of Otago, Christchurch, New Zealand

Publication History

  1. Published Online: 13 JAN 2009
  2. Published Print: 18 APR 2008

Book Series:

  1. The AHA Clinical Series

Book Series Editors:

  1. Elliott Antman

ISBN Information

Print ISBN: 9781405175715

Online ISBN: 9781444300208



  • natriuretic peptides in disease monitoring;
  • B-type natriuretic peptides;
  • BNP/NT-ProBNP - hemodynamic indices marker;
  • left ventricular ejection fraction (LVEF);
  • BNP/NT-proBNP changes in treatment response;
  • prediction of response to therapy;
  • biological variation and total variability determinant


This chapter contains sections titled:

  • Rationale for monitoring clinical status and guiding therapy with BNP/NT-ProBNP

  • Potential roles for BNP/NT-ProBNP in monitoring and guiding treatment of heart failure

  • Intra-individual variability in BNP and NT-ProBNP levels and implications for disease monitoring

  • Conclusion

  • References